SOURCE: Geneart AG

November 20, 2007 01:06 ET

New GENEART Product Line Targets Low-Price Market Segment

REGENSBURG, GERMANY--(Marketwire - November 20, 2007) -



- The  new Mr.  Gene brand  offers exceptional  service to  customers
ordering custom-
  designed genes via an eCommerce platform
-  The  highly  developed  state  of  automation  and  an  attractive
price/value ratio bode well
  for this service in the emerging low-price market segment
- The new platform gives scientists with small budgets easier  access
to synthetic
  genes
- GENEART expects  the new brand  to account  for 25 %  of the  total
sales in the
  medium-term
- Safety ranks as high as ever

Regensburg, November 20, 2007 - Today, the GENEART AG launches 'Mr. Gene' as a second GENEART AG brand. As the global leader in the production of synthetic genes and specialist in the field of synthetic biology, GENEART targets the emerging low-price market sector with its new product lines. Using the Mr. Gene Internet platform (www.mrgene.com) customers can design gene sequences to fit their project plans and then directly order these gene sequences online. The highly automated eCommerce platform ensures an attractive price/value ratio. This eCommerce solution provides easier access to synthetic genes especially for scientists from the academic world, and marks the start of a new era in genetic engineering. The production of synthetic genes now definitely replaces past laborious cloning strategies, and the resulting gene constructs exactly match the customer's project requirements.

The Mr. Gene eCommerce platform ideally complements the GENEART service portfolio. GENEART supports large pharmaceutical companies as well as chemistry and biotechnology enterprises with solutions for their complex research and production projects. Customers delegate their specialists to work directly with GENEART experts, and the result is just the right solution for the presented problem. Using production methods under ISO 9001:2000 certification, the GENEART AG in Regensburg provides first rate system solutions for the customers' research pipelines, which turn into improved therapeutics, vaccines and bioproducts. This involves GENEART services from optimizing gene sequences, the production of synthetic genes all the way to the design of biotherapeutics or large gene libraries. GENEART has developed its own technologies or has obtained necessary licenses. Therefore, no customer information leaves the company and GENEART absolutely safeguards the confidentiality of proprietary and valuable customer information. From now on however, our fully automated Mr. Gene eCommerce platform offers the opportunities to process pure gene synthesis orders online and to optimize genes in a do-it-yourself process at an attractive price. Particularly targeting academic customers, the eCommerce platform favorably positions Mr. Gene in the emerging low-price market for the standardized production of synthetic genes. In contrast to Mr. Gene, the GENEART AG keeps serving the premium market segment for systems solutions and the processing of complex customer projects.

The GENEART AG was able to significantly lower the costs of producing synthetic genes through skillful use of automation and miniaturization. Step by step and as a result of these innovations, the production of synthetic genes has replaced the classical genetic engineering methods and has emerged from a niche application to a standard tool in the pharmaceutical and biotechnological industries. Professor Wagner, CSO of the GENEART AG, elucidates: "The use of synthetic genes in modern biotechnology offers scientists a high level of flexibility. Therefore, universities and public research institutes now also show a strongly growing demand for competitively priced synthetic genes. We are delighted that Mr. Gene will now bring many advantages of using synthetic genes to academic research groups as well." Christian Ehl, CFO of the GENEART AG, comments: "Mr. Gene as a second brand is our answer to the anticipated strong sales growth in this market segment. Our medium term projections put the Mr. Gene sales at 25 percent of the GENEART sales. The operating margin for Mr. Gene products will be equally attractive thanks to the high level of automation using the eCommerce platform."

The same strict biosafety standards apply to Mr. Gene and to the GENEART AG. All Mr. Gene orders will be scrutinized twice for possible risks. Routinely performed standard evaluations of each ordered gene sequence prevent the delivery of potentially hazardous genes to customers.



For further inquiries, please contact:


Bernd Merkl
GENEART AG
Josef-Engert-Str. 11
D-93053 Regensburg
Germany
Phone: +49-(0)941-942 76 - 638
Fax: +49-(0)941-942 76 - 711
ir@geneart.com
www.geneart.com


Frank Ostermair
Better Orange IR & HV AG
Haidelweg 48
D-81241 München
Germany
Phone: +49-(0)89-88 96 906-10
Fax: +49-(0)89-88 96 906-66
info@better-orange.de
www.better-orange.de



Legal Information

This document may contain estimates, prognoses and opinions about company plans and objectives, products or services, future results, opinions about these results or opinions leading up to these results. All these projections into the future are subject to risk, uncertainty and unforeseeable change outside the control of the GENEART Group. Many factors may lead to actual results, which considerably deviate from the given projections for these results.


Background information:

About GENEART AG

In 2000, GENEART entered the gene synthesis market and has since become the global market leader. Today, the company is one of the leading specialists in the synthetic biology field. Experts at GENEART provide key technologies for the development and production of new therapeutics and vaccines. Customers also take advantage of GENEART services to customize enzyme attributes, such as the attributes of enzymes used as detergent additives, and to construct bacteria, which produce complex biopolymers or break down polymers, such as synthetics, petroleum components, etc. Our production and service spectrum spans a wide range, from the production of synthetic genes according to DIN EN ISO 9001-2000, to the creation of gene libraries in the combinatorial biology, to the development and production of DNA-based biologically active substances. The GENEART AG in Regensburg (Germany) and the subsidiary GENEART Inc. in Toronto (Canada) employ more than 180 people. Since May 2006, GENEART is listed on the German Stock Exchange.



About Mr. Gene GmbH

Mr. Gene is an e-commerce platform for ordering synthetic DNA. The website provides the ultimate suite for analysis and optimization of DNA sequences. Users can engineer their sequences to meet their specific requirements. The easy-to-use online tools guide the user from project setup to order processing. All processes are automated, and by acquiring excess capacities from OEM gene manufactures around the world, Mr. Gene can offer the best prices on the market. Our vision is to provide every industrial and academic facility access to these valuable tools, thereby promoting the progression of Life Science research.





Copyright © Hugin ASA 2007. All rights reserved.

Contact Information